| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Nilotinib CML resistant/intolerant to imatinib |
| Brand | Tasigna® |
| Indication | For the treatment of chronic phase CML. |
| Assessment Process | |
| Full submission received from Applicant | 03/01/2008 |
| NCPE assessment completed | 25/02/2008 |
| NCPE assessment outcome | Reimbursement not recommended |
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.